Concomitant treatment using TMZ (150 mg/m2) and CCNU/Lomustine during hfRT, followed by 6 cycles adjuvant TMZ (150-200 mg/m2) for 5 days out of 28 days, the CeTeG protocol, (6-week courses of oral combined CCNU/TMZ (CCNU 100 mg/m2 on day 1, TMZ 100–200 mg/m2 on days 2–6) starting in the first week of radiotherapy) was considered in patients with methylated MGMT promotor in patients with IDH-wt glioblastoma only (n = 6 (2.9%)). This evidence concerns the gene IDH2 and glioblastoma.